“Right now, it’s hard to say what to buy, but it’s best to wait for a reversal. Nifty has strong support at 23,800, with resistance around 24,600 to 24,700. Going short now is not advisable—any positive news could trigger a pullback to 24,500 or 24,600,” says Dharmesh Shah, ICICI Direct. Very interesting data point Soumeet … Read more
“There should be an alternate vendor that can support you, even if at higher prices or higher cost. So, I think that is where the Indian players come in. Remember, last we checked, Indian API exports were around $4 billion and that number compares to China’s API exports of roughly $40 billion,” says Aditya Khemka, … Read more
Brokerage Nomura maintained a neutral rating on HDFC Bank, Kotak Mahindra Bank has a buy rating on InterGlobe Aviation, Jefferies recommended a buy on Piramal Pharma and UBS maintained a buy on Infosys. We have collated a list of recommendations from top brokerage firms from ETNow and other sources: Nomura on HDFC Bank: Neutral| Target … Read more
NEW DELHI: As leaders of the world’s largest economies gather in New Delhi this week for the G20 Summit, a global consensus is emerging among investors recognising the potential of India’s economic and industrial prowess, making several sectors attractive to global investors. We reached out to money managers to filter out P20 (20 portfolio) stocks … Read more
There are a host of corporate actions scheduled for this week. L&T, Crisil, Coforge, Maruti Suzuki and Kotak Mahindra Bank will trade ex-dividend, while Piramal Pharma‘s rights issue’s ex-date is fixed this week. The ex-dividend date is when the price of the equity shares of a company gets adjusted for the dividend payout. It is … Read more
Piramal Pharma has received capital markets regulator Sebi’s go-ahead to raise up to Rs 1,050 crore through rights issue of shares. The pharma firm, which filed draft papers with the regulator in March, obtained its observation letter on July 12, an update with the Securities and Exchange Board of India (Sebi) showed on Tuesday. In … Read more
Piramal Pharma shares are set to debut on the bourses on Wednesday. Last Thursday, the company said it has received Sebi’s go-ahead to list its equity shares on domestic stock exchanges. Following NCLT approval, Piramal Pharma has been demerged from in a bid to simplify the corporate structure. According to the notice, the security shall … Read more